ORIC vs. PHAT, IPHA, ARQT, KPTI, BTAI, AMRX, CGON, AGIO, PTGX, and PTCT
Should you be buying ORIC Pharmaceuticals stock or one of its competitors? The main competitors of ORIC Pharmaceuticals include Phathom Pharmaceuticals (PHAT), Innate Pharma (IPHA), Arcutis Biotherapeutics (ARQT), Karyopharm Therapeutics (KPTI), BioXcel Therapeutics (BTAI), Amneal Pharmaceuticals (AMRX), CG Oncology (CGON), Agios Pharmaceuticals (AGIO), Protagonist Therapeutics (PTGX), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical products" industry.
Phathom Pharmaceuticals (NASDAQ:PHAT) and ORIC Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, community ranking, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.
Phathom Pharmaceuticals currently has a consensus price target of $22.50, suggesting a potential upside of 26.98%. ORIC Pharmaceuticals has a consensus price target of $18.00, suggesting a potential upside of 86.53%. Given ORIC Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe ORIC Pharmaceuticals is more favorable than Phathom Pharmaceuticals.
Phathom Pharmaceuticals received 30 more outperform votes than ORIC Pharmaceuticals when rated by MarketBeat users. Likewise, 71.43% of users gave Phathom Pharmaceuticals an outperform vote while only 69.62% of users gave ORIC Pharmaceuticals an outperform vote.
ORIC Pharmaceuticals has lower revenue, but higher earnings than Phathom Pharmaceuticals. ORIC Pharmaceuticals is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Phathom Pharmaceuticals has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, ORIC Pharmaceuticals has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500.
Phathom Pharmaceuticals' return on equity of 0.00% beat ORIC Pharmaceuticals' return on equity.
99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.1% of ORIC Pharmaceuticals shares are owned by institutional investors. 24.1% of Phathom Pharmaceuticals shares are owned by company insiders. Comparatively, 5.6% of ORIC Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, ORIC Pharmaceuticals had 2 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 6 mentions for ORIC Pharmaceuticals and 4 mentions for Phathom Pharmaceuticals. ORIC Pharmaceuticals' average media sentiment score of 0.34 beat Phathom Pharmaceuticals' score of 0.11 indicating that ORIC Pharmaceuticals is being referred to more favorably in the news media.
Summary
ORIC Pharmaceuticals beats Phathom Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get ORIC Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ORIC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ORIC Pharmaceuticals Competitors List
Related Companies and Tools
